UCSF

UC San Francisco Previously Published Works

Title

The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age.

Permalink

<https://escholarship.org/uc/item/5bv8z964>

Authors

Keller, Roberta L
Eichenwald, Eric C
Hibbs, Anna Maria
et al.

Publication Date

2017-04-01

DOI

10.1016/j.jpeds.2016.12.059

Peer reviewed

The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age

Roberta L. Keller, MD¹, Eric C. Eichenwald, MD², Anna Maria Hibbs, MD³, Elizabeth E. Rogers, MD¹, Katherine C. Wai, MS⁴, Dennis M. Black, PhD⁵, Philip L. Ballard, MD, PhD¹, Jeanette M. Asselin, MS, RRT-NPS⁶, William E. Truog, MD⁷, Jeffrey D. Merrill, MD⁶, Mark C. Mammel, MD⁸, Robin H. Steinhorn, MD⁹, Rita M. Ryan, MD¹⁰, David J. Durand, MD⁶, Catherine M. Bendel, MD¹¹, Ellen M. Bendel-Stenzel, MD⁸, Sherry E. Courtney, MD¹², Ramasubbareddy Dhanireddy, MD¹³, Mark L. Hudak, MD¹⁴, Frances R. Koch, MD¹⁰, Dennis E. Mayock, MD¹⁵, Victor J. McKay, MD¹⁶, Jennifer Helderma, MD¹⁷, Nicolas F. Porta, MD¹⁸, Rajan Wadhawan, MD¹⁹, Lisa Palermo, MS⁵, Roberta A. Ballard, MD¹, on behalf of the TOLSURF Study Group*

Objective To determine the effects of late surfactant on respiratory outcomes determined at 1-year corrected age in the Trial of Late Surfactant (TOLSURF), which randomized newborns of extremely low gestational age (≤ 28 weeks' gestational age) ventilated at 7-14 days to late surfactant and inhaled nitric oxide vs inhaled nitric oxide-alone (control).

Study design Caregivers were surveyed in a double-blinded manner at 3, 6, 9, and 12 months' corrected age to collect information on respiratory resource use (infant medication use, home support, and hospitalization). Infants were classified for composite outcomes of pulmonary morbidity (no PM, determined in infants with no reported respiratory resource use) and persistent PM (determined in infants with any resource use in ≥ 3 surveys).

Results Infants ($n = 450$, late surfactant $n = 217$, control $n = 233$) were 25.3 ± 1.2 weeks' gestation and 713 ± 164 g at birth. In the late surfactant group, fewer infants received home respiratory support than in the control group (35.8% vs 52.9%, relative benefit [RB] 1.28 [95% CI 1.07-1.55]). There was no benefit of late surfactant for No PM vs PM (RB 1.27; 95% CI 0.89-1.81) or no persistent PM vs persistent PM (RB 1.01; 95% CI 0.87-1.17). After adjustment for imbalances in baseline characteristics, relative benefit of late surfactant treatment increased: RB 1.40 (95% CI 0.89-1.80) for no PM and RB 1.24 (95% CI 1.08-1.42) for no persistent PM.

Conclusion Treatment of newborns of extremely low gestational age with late surfactant in combination with inhaled nitric oxide decreased use of home respiratory support and may decrease persistent pulmonary morbidity. (*J Pediatr* 2016;■■■■■■■■■■).

Trial registration ClinicalTrials.gov: NCT01022580

Extreme prematurity carries a risk of ongoing pulmonary morbidity (PM) and resource use following hospital discharge.¹⁻⁴ Interventional trials of both drugs and respiratory support strategies in extremely low gestational age newborns (ELGANs) focus on decreasing the rate of bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age (PMA).⁵⁻⁸ Although BPD is an imperfect

From the ¹Department of Pediatrics, University of California San Francisco, San Francisco, CA; ²Department of Pediatrics, University of Texas, Houston, TX; ³Department of Pediatrics, Case Western Reserve University, Cleveland, OH; ⁴University of California San Francisco School of Medicine, San Francisco, CA; ⁵Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; ⁶Department of Pediatrics, Benioff Children's Hospital Oakland, Oakland, CA; ⁷Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO; ⁸Department of Pediatrics, Children's Hospital and Clinics of Minnesota, St Paul and Minneapolis, MN; ⁹Department of Pediatrics, Children's National Medical Center, Washington, DC; ¹⁰Department of Pediatrics, Medical University of South Carolina, Charleston, SC; ¹¹Department of Pediatrics, University of Minnesota, Minneapolis, MN; ¹²Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR; ¹³Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN; ¹⁴Department of Pediatrics, University of Florida College of Medicine, Jacksonville, FL; ¹⁵Department of Pediatrics, University of Washington, Seattle, WA; ¹⁶Department of Pediatrics, All Children's Hospital, St. Petersburg, FL; ¹⁷Department of Pediatrics, Wake Forest School of Medicine/Forsyth Medical Center, Winston-Salem, NC; ¹⁸Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL; and ¹⁹Department of Pediatrics, Florida Hospital for Children, Orlando, FL

*List of additional members of Trial of Late Surfactant (TOLSURF) Study Group is available at www.jpeds.com (Appendix).

TOLSURF was funded by National Heart, Lung, and Blood Institute (NHLBI; U01 HL094338, U01 HL094355, and UL1 TR000004 [to K.W.]). The NHLBI Scientific Officer, Carol Blaisdell, MD, was present and participated in all Steering Committee meetings as a nonvoting member. Ikaria Inc and ONY Inc provided drugs for the conduct of the trial but had no input into study design, data analysis, data interpretation or manuscript preparation. R.S. serves as Associate Editor of *The Journal of Pediatrics*. The other authors declare no conflicts of interest.

Portions of the study were presented as an abstract at the meeting of the Pediatric Academic Societies, April 30-May 3, 2016, Baltimore, MD.

0022-3476/\$ - see front matter. © 2016 Elsevier Inc. All rights reserved.

<http://dx.doi.org/10.1016/j.jpeds.2016.12.059>

BD	Bronchodilator
BPD	Bronchopulmonary dysplasia
ELGAN	Extremely low gestational age newborn
GA	Gestational age
ICS	Inhaled corticosteroids
INO	Inhaled nitric oxide
NO CLD	Inhaled Nitric Oxide to Prevent Chronic Lung Disease
PM	Pulmonary morbidity
PMA	Postmenstrual age
RB	Relative benefit
TOLSURF	Trial of Late Surfactant

predictor of later PM,^{1,4,9} clinical trials have not reported broadly accepted later respiratory outcomes. Outcomes previously evaluated at 1–2 years of age include respiratory symptoms, medication use, respiratory exacerbations, and hospitalizations due to respiratory disease.^{2–4,10–12}

The Trial of Late Surfactant (TOLSURF) was a randomized, controlled, masked clinical trial in which ELGANs at high risk for BPD who remained intubated in the second week of life were randomized to late surfactant (up to 5 doses) and inhaled nitric oxide (iNO) vs iNO alone.¹³ We found no difference in the primary outcome of survival without BPD at 36 weeks' PMA. A potential benefit of treatment with late surfactant, however, emerged with a later respiratory assessment at 40 weeks' PMA (term). Data on respiratory resource use after hospital discharge were collected. We sought to determine whether there were effects of late surfactant on several clinically relevant respiratory outcomes determined through 1-year corrected age. We hypothesized that late surfactant and iNO would improve respiratory outcomes compared with iNO alone.

Methods

The TOLSURF study ([ClinicalTrials.gov: NCT01022580](https://clinicaltrials.gov/ct2/show/study/NCT01022580)) has been described in detail.¹³ Parental informed consent for participation was obtained under institutional review board approval at 25 US hospitals. In brief, 511 infants ≤ 28 0/7 weeks' gestational age (GA) underwent stratified randomization (<26 weeks' GA or ≥ 26 weeks' GA) by site to late surfactant and iNO vs iNO alone at 7–14 days ($n = 252$ and 259 , respectively). Calfactant (Infasurf; ONY Inc, Amherst, New York) was administered in standard doses every 1–3 days for up to 5 doses in the late surfactant group. Control (iNO alone) infants had no intervention (sham procedure behind a screen to maintain blinding). All infants received iNO for a 25-day course, per the protocol of our previous study of Nitric Oxide to Prevent Chronic Lung Disease (NO CLD).^{14,15} The primary outcome of TOLSURF was survival without BPD, determined by oxygen/flow reduction challenge at 36.0 ± 1 weeks' PMA. Infants on nasal cannula support with effective fraction of inspired oxygen < 0.30 who remained hospitalized at 40 weeks' PMA had a repeat assessment. No statistically significant differences were identified in primary or secondary outcomes during the neonatal hospitalization.¹³ Clinical study personnel and families remained blinded to treatment group assignment through the follow-up period (completed February 2016). Unblinded outcomes were reviewed periodically by a data safety monitoring board appointed by the National Institutes of Health.

Parents/caregivers were surveyed at 3, 6, 9, and 12 months' corrected age (for prematurity) for interval events since discharge or last contact. Responses to questions regarding respiratory medication prescription, hospitalization for respiratory illness, and home respiratory support (supplemental oxygen by nasal cannula or tracheostomy with or without assisted ventilation/oxygen) were collated. Specific respiratory medication categories queried were inhaled bronchodilators (BD), inhaled corticosteroids (ICS), diuretics, systemic steroids, and

pulmonary vasodilators. We also asked caregivers if they had been told by a medical professional that their child had wheeze on auscultation. These questions were posed over the same time interval, since the last contact.

Respiratory Outcomes at 1-Year Corrected Age

We focused the analysis of PM following neonatal discharge on caregiver-reported health resource use for respiratory indications in 3 domains (medications, hospitalization, and home support) using a short recall interval. We predetermined several outcomes to quantify the degree and type of morbidity experienced by these infants. Our primary outcomes were PM and persistent PM. We assigned an outcome of no PM to infants whose caregivers reported no medications, hospitalizations, or home respiratory support on any survey through 12 months' corrected age. We assigned an outcome of any PM to all other infants. We defined persistent PM in infants with morbidity on any domain on at least 3 surveys. Infants with morbidity on 2 or fewer surveys were classified as no persistent PM.

A committee of investigators who remained blinded to treatment assignment evaluated 37 infants with incomplete survey data who were unclassified for one or both outcomes, for adjudication of missing outcomes. Using simple imputation when data were missing between 2 other time points (eg, no resource use reported), and additional respiratory resource use data collected during follow-up visits in the second year of life and among infants with prolonged neonatal hospitalizations beyond 3 months' corrected age, we were able to impute either missing PM or persistent PM for 8 infants, and both for 1 infant. Four infants had no follow-up data, 2 had insufficient data for both outcomes (but contributed other data on resource use), and the remainder were unable to be classified for one missing outcome (Figure 1; available at www.jpeds.com). Infants were classified as a wheezing phenotype if caregivers reported any ICS or BD use or wheeze (vs no wheezing phenotype). They were subclassified into 4 ordered categories of wheezing phenotype: likely (ICS with/without BD use), probable (BD use with/without wheeze), possible (wheeze without BD/ICS use), or none (no ICS, BD, or wheeze).

Statistical Analyses

To estimate treatment effect, we used generalized estimating equations to account for clustering of siblings. Analyses of baseline characteristics and potential modifiers of infant lung disease did not account for clustering. All analyses were by intent-to-treat, based on initial randomized allocation. Because of the known impact of sociodemographic factors in postdischarge outcomes among infants born extremely preterm, we planned a priori to adjust estimations of treatment effect for our primary outcomes (PM and persistent PM) for differences ($P < .05$) in baseline characteristics noted between groups.

Results

Patients were enrolled between January 2010 and September 2013. Of 471 infants alive at 36 weeks' PMA, 455 who remained in the study were discharged alive and 5 infants died

Table I. Baseline characteristics and neonatal respiratory outcomes of infants discharged alive by treatment group (late surfactant vs control)

Characteristics	Follow-up cohort (n = 450)	Late surfactant (n = 217)	Control (n = 233)	P value
GA, wk	25.3 ± 1.2	25.3 ± 1.2	25.3 ± 1.2	.90
<26 0/7 wk	310 (68.9)	148 (68.2)	162 (69.5)	.76
Birth weight, g	713 ± 164	715 ± 174	711 ± 154	.81
Intrauterine growth restriction	73 (16.2)	40 (18.4)	33 (14.2)	.22
Antenatal steroids	388 (86.2)	184 (84.8)	204 (87.6)	.11
Male sex	248 (55.1)	124 (57.1)	124 (53.2)	.40
Multiple gestation	139 (30.9)	56 (25.8)	83 (35.6)	.02
Multiple siblings enrolled	102 (22.7)	41 (18.9)	61 (26.2)	.07
Maternal characteristics				
Race/ethnicity				.47
White, non-Hispanic	220 (48.9)	101 (46.5)	119 (51.1)	
African American	159 (35.3)	82 (37.8)	77 (33.0)	
Hispanic	50 (11.1)	21 (9.7)	29 (12.4)	
Asian	13 (2.9)	5 (2.1)	8 (3.7)	
Other	8 (1.8)	5 (2.3)	3 (1.3)	
Age, y	28.8 ± 6.4	27.8 ± 6.1	29.8 ± 6.6	.0007
Education				.06
High school not complete	56 (12.4)	23 (10.6)	33 (14.2)	
High school graduate or some college	227 (50.4)	123 (56.7)	104 (44.6)	
College graduate ± graduate school	166 (36.9)	71 (32.7)	95 (40.8)	
Unknown	1 (0.2)	0	1 (0.4)	
Neonatal respiratory outcomes				
BPD at 36 wk PMA	291 (64.7)	140 (64.5)	151 (64.8)	.95
BPD at 40 wk PMA	165 (36.7)	71 (32.7)	94 (40.3)	.09
Duration of mechanical ventilation (d)	41.9 ± 30.4	42.3 ± 30.6	41.4 ± 30.3	.77

Data are mean ± SD or n (%).

P value by *t* test or χ^2 .

Intrauterine growth restriction ≤ 10th percentile for GA per fetal growth curves derived from Fenton and Kim.¹⁶

after discharge without further follow-up data collected (Figure 1). Consistent with characteristics of the original study participants, infants with 1-year follow up were predominantly male and averaged 25.3 ± 1.2 weeks' gestation, with birth weight 713 ± 164 g (Table I).^{13,16} The duration of mechanical ventilation was prolonged; 65% of infants had a diagnosis of BPD at 36 weeks' PMA, and 37% had a diagnosis of BPD at 40 weeks' PMA. Eleven infants had undergone tracheostomy, 6 were receiving assisted ventilation at home, and 1 was lost to follow-up. There were significant baseline differences between late surfactant-treated and control infants. Namely, infants in the late surfactant group had mothers who were 2 years younger (with a trend to lower educational attainment), and there were fewer products of multiple gestation.

We also evaluated for differences in potential modifiers of infant lung disease identified from the caregiver discharge survey. These included potential environmental exposure to tobacco smoke, anticipated breast milk feeding, exposure to furry pets, private insurance status, and parental history of asthma. There were no significant differences by treatment group, although there was a trend toward a lower proportion of parents with asthma in the late surfactant group (14.5% vs 21.9%, *P* = .05) (Table II; available at www.jpeds.com).

Surveys were completed near the target dates (3.2 ± 0.6, 6.2 ± 0.7, 9.1 ± 0.6, and 12.3 ± 0.8 months' corrected age), with 421, 423, 413, and 414 fully completed surveys at 3, 6, 9, and 12 months' corrected age, respectively. We were able to classify 439 infants (97.6%) for PM (no PM vs any PM) and 426

infants for persistent PM (no persistent PM vs persistent PM); 25% (110/439) of the infants had no PM, and 36% (153/426) had persistent PM. Of infants who reported resource use, 96 had morbidity at only 1 survey, 80 at 2 surveys, 73 at 3 surveys, and 80 at 4 surveys. The distribution of respiratory outcomes of interest at 1-year corrected age by treatment group is shown (Table III). No benefits of late surfactant on composite outcomes were seen in unadjusted analyses: relative benefit (RB) of treatment with late surfactant was 1.27 (95% CI 0.89-1.81; *P* = .19) for no PM and 1.01 (95% CI 0.87-1.17; *P* = .91) for no persistent PM. After adjustment for baseline imbalances (maternal age and multiple gestation status), the RB of treatment with late surfactant increased to RB 1.40 (95% CI 0.96-2.04; *P* = .08) for no PM, and RB 1.24 (95% CI 1.08-1.42; *P* = .003) for no persistent PM. With adjustment for parental history of asthma in sensitivity analyses, there were no significant benefits of treatment for either no PM nor no persistent PM. There also was no difference between groups for our definition of wheezing phenotype.

To further describe the relationship of treatment to postdischarge domains of PM, we plotted overall resource use and use in each domain (medications, home support, and hospitalizations) at each survey time point by treatment group (Figure 2, A-D). Resource use was greater in the control group at all time points except 9 months. The treatment effect on these domains was limited. The overall proportion of infants in the late surfactant group that received home respiratory support (predominantly home oxygen use) over the follow-up period,

Table III. Respiratory outcomes at 1-year corrected age by treatment group

Treatment groups	Follow-up cohort	Late surfactant	Control	RB (95% CI)
No PM	110/439 (25.1)	59/210 (28.1)	51/229 (22.3)	1.27 (0.89-1.81)
Persistent PM	153/426 (35.9)	74/208 (35.6)	79/218 (36.2)	1.01 (0.87-1.17)
Wheezing phenotype				
Dichotomous				
Any	291/436 (66.7)	140/210 (66.7)	151/226 (66.8)	0.99 (0.74-1.31)
Ordered*				
ICS ± BD	134/436 (30.7)	66/210 (31.4)	68/226 (30.1)	
BD ± wheeze	108/436 (24.8)	51/210 (24.3)	57/226 (25.2)	
Wheeze only	49/436 (11.2)	23/210 (11.0)	26/226 (11.5)	
None	145/436 (33.3)	70/210 (33.3)	75/226 (33.3)	
Postdischarge morbidity domains				
Respiratory hospitalization	121/428 (28.3)	60/205 (29.3)	61/223 (27.4)	0.97 (0.85-1.10)
Home respiratory support	198/431 (45.9)	80/208 (38.5)	118/223 (52.9)	1.28 (1.07-1.55)
Any respiratory medication exposure	277/438 (63.2)	132/211 (62.6)	145 (63.9)	1.07 (0.82-1.40)
Postdischarge medication use				
Diuretic	89/430 (20.7)	40/207 (19.3)	49/223 (22.0)	1.04 (0.94-1.15)
BD	221/435 (50.8)	110/210 (52.4)	111/225 (49.3)	0.95 (0.77-1.16)
ICS	134/430 (31.2)	66/208 (31.7)	68/222 (30.6)	0.99 (0.87-1.13)
Systemic steroid	70/430 (16.3)	37/208 (17.8)	33/222 (16.3)	0.97 (0.89-1.06)

Data are n/N (%) and RB (95% CI).

RB by generalized estimating equation, accounting for clustering of siblings.

*P value .97 by χ^2 .

however, was lower (RB 1.28, 95% CI 1.07-1.55; [Table III](#)), consistent with the observed pattern of less support at each time point. We also evaluated the relationship of reported exposures to respiratory medication classes (diuretics, BD, ICS, systemic steroids) and treatment group, at each survey ([Figure 2](#), E-H). Diuretic use tended to be greater in controls and BD use tended to be greater in the late surfactant group. Only 9 infants reported pulmonary vasodilator therapy, so this exposure was not evaluated further.

Discussion

We demonstrated no substantial benefit of late surfactant as administered in TOLSURF on novel respiratory outcomes determined at 1-year corrected age; however, there was significantly less use of home respiratory support over the first year in infants in the late surfactant group, consistent with the trend shown previously toward decreased need for oxygen at 40 weeks' PMA.¹³ Because no substantial adverse effects of late surfactant were found during the neonatal hospitalization, the current data further support the safety of late surfactant therapy in high-risk ELGAN.

Many randomized trials in ELGAN aim to improve infant respiratory status during the neonatal hospitalization. A number of these have failed to identify benefit in the neonatal period but subsequently have demonstrated advantage in at least one measure of respiratory status at follow-up.^{4-6,10,12,17} Although Zivanovic et al¹⁷ found no difference in symptomatic lung disease at follow-up, measures of air flow obstruction and diffusing capacity were less compromised in children who were randomized to primary high-frequency ventilation compared with conventional mechanical ventilation. Davis et al¹⁰ demonstrated a trend toward fewer respiratory exacerbations requiring asthma medications by 1-year corrected age in infants born preterm receiving antioxidant therapy with recombinant human superoxide dismutase compared with controls. Similarly, Stevens et al⁴ demonstrated fewer respiratory exacerbations by 22 months' corrected age in children randomized at birth to primary nasal continuous positive airway pressure vs intubation with surfactant administration and mechanical ventilation. Akin to our findings, infants who were intubated and mechanically ventilated at 14 days of age and received a single dose of poractant alfa (Curosurf; Chiesi USA, Inc, Cary, North Carolina) had lower rates of respiratory hospitalization by 9.5 months' corrected age, although there were

Figure 2. Proportion of infants with respiratory resource use at each survey time point, 3, 6, 9, and 12 months' corrected age, in late surfactant and control groups: **A**, Total resource use, **B**, respiratory medication exposure, **C**, home respiratory support, **D**, hospitalization for respiratory cause, and **E**, diuretics, **F**, BD, **G**, ICS, and **H**, systemic steroid exposure.

no other significant differences in respiratory status during the neonatal hospitalization or among other follow-up outcomes.¹²

The choice of respiratory outcomes after neonatal discharge in these and other studies has varied broadly and has included symptoms, respiratory resource use (medications, hospitalization, and home respiratory support), and measures of pulmonary function. Early and persistent decreases in pulmonary function are likely to have repercussions throughout life, even in the absence of symptoms.^{18,19} Thus, pulmonary function testing can yield data that are relevant to clinicians and families; however, there is also a burden on children and families associated with persistent clinically symptomatic lung disease, related to repeated hospitalizations, exposures to multiple medications with potentially adverse effects, cost, and other effects.¹⁻⁴

For some clinical trials, multiple single areas (domains) of symptoms or resource use have been evaluated.^{2,4} The NO CLD trial, for instance, showed benefit of iNO therapy in high-risk infants born preterm both with neonatal respiratory outcomes and in multiple domains of postdischarge respiratory resource use at 1-year corrected age, including medication use and home respiratory support.² The Surfactant Positive Pressure, and Pulse Oximetry Randomized Trial (SUPPORT) trial, however, which investigated primary delivery room management with continuous positive airway pressure, did not show an effect on diagnosis of BPD at 36 weeks' PMA but did demonstrate lower rates of wheeze and respiratory exacerbations at 6-22 months' corrected age.⁴ Composite outcomes of respiratory status have had limited application in neonatal clinical trials, and prospective data collection toward outcomes as we have developed and analyzed in the current study have not been used.⁹ Although both resource use and symptom reporting can be affected by socioeconomic status, biological variables also demonstrate associations with these later outcomes, making them plausible primary or secondary trial outcomes.²⁰⁻²⁵

This is analogous to the use of neurodevelopmental impairment as an outcome, which often is assessed at 18-24 months' corrected age and also is influenced by socioeconomic status.²⁶

Given the young age of our cohort at the time of analysis, we explored a limited "wheezing phenotype" in this study, derived only from reported inhaled medication exposure and wheeze. We did not see a signal for treatment effect on this outcome, nor for the medication components of the outcome. This observation suggests that any effect of late surfactant with iNO on persistent lung disease may be distinct from wheezing illness commonly present in former infants born preterm (which occur across the spectrum of preterm birth).²⁷ Previous studies evaluating childhood respiratory outcomes before and after the advent of surfactant replacement therapy showed mild improvements or no change in prevalence of wheezing illness or airway obstruction in the surfactant era, despite an increase in survival of more immature infants.^{28,29} These findings are in contrast to our previous findings with iNO alone, wherein beneficial effects of iNO in the NO CLD study were seen on both classes of inhaled medications.² Finally, although data supporting the association of parental asthma and preterm respiratory outcomes are variable, we did plan a sensitivity analysis because this characteristic is of interest with respect to childhood wheezing illness.^{30,31}

With lack of effect on our wheezing phenotype, it is of interest that the treatment effect we did demonstrate was on the use of home respiratory support. In contrast to wheezing illness, the use of home oxygen is more specific to infants born extremely preterm than to the broader population of preterm infants as a whole.³² Thus, the effect of late surfactant may be more specific to the perturbed lung development of ELGAN. Diuretics similarly are more common in this population, although we failed to show a significant benefit of late surfactant on diuretic exposure.³³ Notably, the results of the current study represent the effects of late surfactant in infants receiving

iNO, which, when administered by this protocol in the NO CLD study, decreased home oxygen use and respiratory medication exposure from all drug classes. Thus, the effects of late surfactant administration alone (without iNO), as administered by Hascoët et al,¹² may differ from the effects seen in the current study.

The data for the current study were collected by caregiver recall, which may raise concerns regarding its accuracy. Previous studies, however, have shown that parents can report important events from the last 12 months (such as hospitalizations and medical visits for asthma and bronchitis), with moderate-to-substantial (85%-95%) agreement with medical records.^{34,35} In addition, test-retest reliability for questions related to respiratory illness administered to parents of preterm infants at 6 months' corrected age revealed substantial-to-perfect agreement over the 2 tests, and strong internal consistency.³⁶ Thus, within the short time frame of surveys for the current study, we would expect good accuracy and reliability of parent responses.

In conclusion, compared with iNO alone, late surfactant decreases the use of home respiratory support following initial hospital discharge. Unfortunately, we did not demonstrate a substantial benefit of late surfactant on our novel, composite respiratory outcomes. One possible explanation for the lack of benefit is that we didn't treat with late surfactant frequently enough to achieve a persistent effect on lung function.^{13,37} Regardless, these novel respiratory outcomes are clinically relevant and should be considered for the assessment of the effects of interventions in neonatal clinical trials. Neurodevelopmental outcomes for this trial will be reported separately; however, from the current data, late surfactant with iNO appears to be a safe intervention, with no adverse effects demonstrated at 1-year corrected age. These data are reassuring as we consider using surfactant as a vehicle for instillation of local corticosteroids to the lung, which may prove an effective therapy to prevent BPD in high-risk ELGAN.³⁸ ■

We thank Nancy Newton, MS, RN, CCRP (NHLBI U01 HL094338), the project director for the first 4 years of the trial; Karin L. Knowles (NHLBI U01 HL094338), for managing the administrative and regulatory aspects of the study; Carol Blaisdell, MD (funded by the National Institutes of Health), and the Data Safety Monitoring Board for their service; the intensive care nursery and high-risk infant follow-up clinic staffs who made this study possible; and the children and families who participated in the study.

Submitted for publication Aug 30, 2016; last revision received Oct 31, 2016; accepted Dec 19, 2016

Reprint requests: Roberta L. Keller, MD, Department of Pediatrics, University of California San Francisco, UCSF Box 0734, San Francisco, CA 94143. E-mail: keller@peds.ucsf.edu

References

1. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. *Pediatrics* 2005;116:1353-60.
2. Hibbs AM, Walsh MC, Martin RJ, Truog WE, Lorch SA, Alessandrini E, et al. One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial. *J Pediatr* 2008;153:525-9.
3. Watson RS, Clermont G, Kinsella JP, Kong L, Arendt RE, Cutter G, et al. Clinical and economic effects of iNO in premature newborns with respiratory failure at 1 year. *Pediatrics* 2009;124:1333-43.
4. Stevens TP, Finer NN, Carlo WA, Szilagyi PG, Phelps DL, Walsh MC, et al. Respiratory outcomes of the Surfactant Positive Pressure and Oximetry Randomized Trial (SUPPORT). *J Pediatr* 2014;165:240-9, e4.
5. Johnson AH, Peacock JL, Greenough A, Marlow N, Limb ES, Marston L, et al. High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. *N Engl J Med* 2002;347:633-42.
6. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, et al. Early CPAP versus surfactant in extremely preterm infants. *N Engl J Med* 2010;362:1970-9.
7. Kirpalani H, Millar D, Lemyre B, Yoder BA, Chiu A, Roberts RS, et al. A trial comparing noninvasive ventilation strategies in preterm infants. *N Engl J Med* 2013;369:611-20.
8. Beam KS, Aliaga S, Ahlfeld SK, Cohen-Wolkowicz M, Smith PB, Laughon MM. A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants. *J Perinatol* 2014;34:705-10.
9. Davis PG, Thorpe K, Roberts R, Schmidt B, Doyle LW, Kirpalani H, et al. Evaluating "old" definitions for the "new" bronchopulmonary dysplasia. *J Pediatr* 2002;140:555-60.
10. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W, et al. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. *Pediatrics* 2003;111:469-76.
11. Manley BJ, Makrides M, Collins CT, McPhee AJ, Gibson RA, Ryan P, et al. High-dose docosahexaenoic acid supplementation of preterm infants: respiratory and allergy outcomes. *Pediatrics* 2011;128:e71-7.
12. Hascoët JM, Picaud JC, Ligi I, Blanc T, Moreau F, Pinturier MF, et al. Late surfactant administration in very preterm neonates with prolonged respiratory distress and pulmonary outcome at 1 year of age: a randomized clinical trial. *JAMA Pediatr* 2016;170:365-72.
13. Ballard RA, Keller RL, Black DM, Ballard PL, Merrill JD, Eichenwald EC, et al. Randomized trial of late surfactant treatment in ventilated preterm infants receiving inhaled nitric oxide. *J Pediatr* 2016;168:23-9, e4.
14. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. *N Engl J Med* 2006;355:343-53.
15. Ballard RA. Inhaled nitric oxide in preterm infants—correction. *N Engl J Med* 2007;357:1444-5.
16. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. *BMC Pediatr* 2013;13:59.
17. Zivanovic S, Peacock J, Alcazar-Paris M, Lo JW, Lunt A, Marlow N, et al. Late outcomes of a randomized trial of high-frequency oscillation in neonates. *N Engl J Med* 2014;370:1121-30.
18. Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. *Lancet* 2007;370:758-64.
19. Islam JY, Keller RL, Aschner JL, Hartert TV, Moore PE. Understanding the short and long-term respiratory outcomes of prematurity and bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2015;192:134-56.
20. Wynne J, Hull D. Why are children admitted to the hospital? *Br Med J* 1977;2:1140-2.
21. Greenough A, Limb E, Marston L, Marlow N, Calvert S, Peacock J. Risk factors for respiratory morbidity in infancy after very premature birth. *Arch Dis Child Fetal Neonatal Ed* 2005;90:F320-3.
22. Alpern ER, Stanley RM, Gorelick MH, Donaldson A, Knight S, Teach SJ, et al. Epidemiology of a pediatric emergency medicine research network: the PECARN Core Data Project. *Pediatr Emerg Care* 2006;22:689-99.
23. Michel G, Silverman M, Strippoli MP, Zwahlen M, Brooke AM, Grigg J, et al. Parental understanding of wheeze and its impact on asthma prevalence estimates. *Eur Respir J* 2006;28:1124-30.
24. Mohangoo AD, de Koning HJ, Hafkamp-de Groen E, van der Wouden JC, Jaddoe VW, Moll HA, et al. A comparison of parent-reported wheezing

- or shortness of breath among infants as assessed by questionnaire and physician-interview: the Generation R study. *Pediatr Pulmonol* 2010;45:500-7.
25. Pryhuber GS, Maitre NL, Ballard RA, Cifelli D, Davis SD, Ellenberg JH, et al. Prematurity and Respiratory Outcomes Program (PROP): study protocol of a prospective multicenter study of respiratory outcomes of preterm infants in the United States. *BMC Pediatr* 2015;15:37.
 26. Doyle LW, Cheong JL, Burnett A, Roberts G, Lee KJ, Anderson PJ, et al. Biological and social influences on outcomes of extreme-preterm/low-birth weight adolescents. *Pediatrics* 2015;136:e1513-20.
 27. Been JV, Lugtenberg MJ, Smets E, van Schayck CP, Kramer BW, Mommers M, et al. Preterm birth and childhood wheezing disorders: a systematic review and meta-analysis. *PLoS Med* 2014;11:e1001596.
 28. Palta M, Sadek-Badawi M, Sheehy M, Albanese A, Weinstein M, McGuinness G, et al. Respiratory symptoms at age 8 years in a cohort of very low birth weight children. *Am J Epidemiol* 2001;154:521-9.
 29. Doyle LW, Victorian Infant Collaborative Study Group. Respiratory function at age 8-9 years in extremely low birth weight/very preterm children born in Victoria in 1991-1992. *Pediatr Pulmonol* 2006;41:570-6.
 30. Halterman JS, Lynch KA, Conn KM, Hernandez TE, Perry TT, Stevens TP. Environmental exposures and respiratory morbidity among very low birth weight infants at 1 year of life. *Arch Dis Child* 2009;94:28-32.
 31. Teune MJ, van Wassenaer AG, van Buuren S, Mol BW, Opmeer BC, Dutch POPS Collaborative Study Group. Perinatal risk-indicators for long-term respiratory morbidity among preterm or very low birth weight neonates. *Eur J Obstet Gynecol Reprod Biol* 2012;163:134-41.
 32. Lagatta JM, Clark RH, Brousseau DC, Hoffmann RG, Spitzer AR. Varying patterns of home oxygen use in infants at 23-43 weeks' gestation discharged from United States neonatal intensive care units. *J Pediatr* 2013;163:976-82, e2.
 33. Laughon MM, Chantala K, Aliaga S, Herring AH, Hornik CP, Hughes R, et al. Diuretic exposure in premature infants from 1997 to 2011. *Am J Perinatol* 2015;32:49-56.
 34. Pless CE, Pless IB. How well they remember. The accuracy of parent reports. *Arch Pediatr Adolesc Med* 1995;149:553-8.
 35. D'Souza-Vazirani D, Minkovitz CS, Strobino DM. Validity of maternal report of acute health care use for children younger than 3 years. *Arch Pediatr Adolesc Med* 2005;159:167-72.
 36. Boggs E, Minich N, Hibbs AM. Performance of commonly used respiratory questionnaire items in a cohort of infants born preterm. *Open J Pediatr* 2013;3:260-5.
 37. Keller RL, Merrill JD, Black DM, Steinhorn RH, Eichenwald EC, Durand DJ, et al. Late administration of surfactant replacement therapy increases surfactant protein-B content: a randomized pilot study. *Pediatr Res* 2012;72:613-9.
 38. Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2016;193:86-95.

Appendix

Additional members of the TOLSURF Study Group include the following:

UCSF Benioff Children's Hospital, San Francisco, California: Suzanne Hamilton Strong, RN, Jill Immamura-Ching, RN, Margaret Orfanos-Villalobos, RN, Cassandra Williams, RN; Alta Bates Summit Medical Center, Berkeley, California, and UCSF Benioff Children's Hospital Oakland, Oakland, California: Dolia Horton, RRT, Loretta Pacello, RCP, April Willard, RN; Children's Mercy Hospital, Kansas City, Missouri: Cheryl Gauldin, RN, Anne Holmes, RN, Patrice Johnson, RRT, Kerrie Meinert, RRT; Women and Children's Hospital of Buffalo, Buffalo, New York: Anne Marie Reynolds, MD, Janine Lucie, NNP, Patrick Conway, Michael Sacilowski, Michael Leadersdorff, RRT, Pam Orbank, RRT, Karen Wynn, NNP; Anne and Robert H. Lurie Children's Hospital/Northwestern University, Chicago, Illinois: Maria deUngria, MD, Janine Yasmin Khan, MD, Karin Hamann, RN, Molly Schau, RN, Brad Hopkins, RRT, James Jensen, RRT; Texas Children's Hospital, Houston, Texas: Carmen Garcia, RN; Stony Brook University Hospital, Stony Brook, New York: Aruna Parekh, MD, Jila Shariff, MD, Rose McGovern, RN, Jeff Adelman, RRT, Adrienne Combs, RN, Mary Tjersland, RRT; University of Washington, Seattle, Washington: Elizabeth Howland, Susan Walker, RN, Jim Longoria, RRT, Holly Meo, RRT; University of Texas Health Science Center, Houston, Texas: Amir Khan, MD, Georgia McDavid, RN, Katrina Burson, RN, BSN, Richard Hinojosa, BSRT, RRT, Christopher Johnson, MBA, RRT, Karen Martin, RN, BSN, Sarah Martin, RN, BSN, Shawna Rogers, RN, BSN, Sharon Wright, MT; University of Florida College of Medicine, Jacksonville, UF Health Shands Hospital, and Wolfson Children's Hospital, Jacksonville, Florida: Kimberly Barnette, RRT, Amanda Kellum, RRT, Michelle Burcke, RN, Christie Hayes, RRT, Stephanie Chadwick, RN, Danielle Howard, RN, Carla Kennedy, RRT, Renee Prince, RN; Wake Forest School of Medicine and Forsyth Medical Center, Winston-Salem, North Carolina: Michael O'Shea MD, Beatrice Stefanescu, MD, Kelly Warden, RN, Patty Brown, RN, Jennifer Griffin, RRT, Laura Conley, RRT; University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota: Michael Georgieff, MD, Bridget Davern, Marla Mills, RN, Sharon Ritter, RRT; Medical University of South Carolina, Charleston, South Carolina: Carol Wagner, MD, Deanna Fanning, RN, Jimmy Roberson, RRT; Children's Hospitals and Clinics of Minnesota, St Paul, Minnesota: Andrea Lampland, MD, Pat Meyers, RRT, Angela Brey, RRT; Children's Hospitals and Clinics of

Minnesota, Minneapolis, Minnesota: Neil Mulrooney MD, Cathy Worwa, RRT, Pam Dixon, RN, ANM, Gerald Ebert, RRT-NPS, Cathy Hejl, RRT, Molly Maxwell, RT, Kristin McCullough, RN; University of Tennessee Health Science Center, Memphis, Tennessee: Mohammed T. El Abiad, MD, Ajay Talati, MD, Sheila Dempsey, RN, Kathy Gammage, RRT, MBA, Gayle Gower, RN, Kathy James, RRT, Pam LeNoue, RN; All Children's Hospital, St. Petersburg, Florida: Suzi Bell, DNP, Dawn Bruton, RN, BSN, CCRP, Michelle Beaulieu, DNP, Richard Williams, RRT; Florida Hospital for Children, Orlando, Florida: Robin Barron-Nelson, RN, Shane Taylor, RRT; Arkansas Children's Hospital and University of Arkansas Medical Sciences, Little Rock, Arkansas: Carol Sikes, RN, Gary Lowe, RRT, Betty Proffitt, RRT.

Clinical Coordinating Center: University of California San Francisco, San Francisco, California: Cheryl Chapin, Hart Horneman, Karin Hamann, RN, Susan Kelley, RRT, Karin Knowles, Nancy Newton, RN, MS.

Data Coordinating Center: University of California San Francisco, San Francisco, California: Eric Vittinghoff, PhD, Jean Hietpas, Laurie Denton, Lucy Wu.

Data Safety Monitoring Board: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio: Alan Jobe, MD (Chair 2009-2010); UH Rainbow Babies and Children's Hospital, Cleveland, Ohio: Avroy Fanaroff, MD (Chair 2010-2016); EMMES Corporation, Rockville, Maryland: Traci Clemons, PhD; Boston University School of Public Health, Boston, Massachusetts: Leonard Glantz, JD; Wake Forest School of Medicine, Winston-Salem, North Carolina: David Reboussin, PhD; Stanford University, Stanford, California: Krisa Van Meurs, MD (2009-2010); Johns Hopkins University, Baltimore, Maryland: Marilee Allen, MD (2010-2016); Women and Infants Hospital, Providence, Rhode Island: Betty Vohr, MD.

Clinical Steering Committee: University of California, San Francisco Benioff Children's Hospital San Francisco, San Francisco, California: Roberta Ballard, MD, Philip Ballard, MD, PhD, Roberta Keller, MD, Elizabeth Rogers, MD, Nancy Newton, MS, RN; University of California, San Francisco, San Francisco, California: Dennis Black, PhD; National Heart, Lung and Blood Institute: Carol Blaisdell, MD; UCSF Benioff Children's Hospital Oakland, Oakland, California: David Durand, MD, Jeffrey Merrill, MD, Jeanette Asselin, MS, RRT; University of Texas Health Science Center, Houston, Texas: Eric Eichenwald, MD; Children's Hospital and Clinics of Minnesota, St Paul, Minnesota: Mark Mammel, MD; Medical University of South Carolina, Charleston, South Carolina: Rita Ryan, MD; Children's Mercy Hospital, Kansas City, Missouri: William Truog, MD.

Figure 1. Patient flow diagram. Deaths and study withdrawals before neonatal discharge detailed in Ballard et al.¹³ Rx, treated.

Table II. Potential modifiers of postdischarge PM by treatment group (late surfactant vs control)

Modifiers	Follow-up cohort (n = 432)*	Late surfactant (n = 211)	Control (n = 221)	P value
Breast milk (full or partial) anticipated	195 (45.1)	91 (43.1)	104 (47.1)	.41
Furry pet in home	178 (41.2)	85 (40.3)	93 (42.1)	.70
Young child exposure anticipated	228 (52.8)	115 (54.5)	113 (51.1)	.48
Potential ETS exposure	105 (24.3)	51 (24.2)	54 (24.4)	.95
Private insurance	170/430 (39.5)	78/210 (37.1)	92/220 (41.8)	.32
Asthma in parent	77/422 (18.2)	30/207 (14.5)	47/215 (21.9)	.05

ETS, environmental tobacco smoke.
Data are n/N (%).
P value by χ^2 .
“Young child exposure anticipated” was classified as yes if caregiver reported another child <5 years in the home or anticipated a young child at day care.
“Potential ETS exposure” was classified as yes if caregiver reported (1) a parent smokes, (2) there is a smoker living in the home, (3) smoking is allowed in home, or (4) the child will travel in vehicle where smoking is permitted.
“Breast milk anticipated” was classified as yes if caregiver reported either a breast milk only diet or combination of breast milk and formula at discharge.
*Missing data for infants not discharged to their biological parents’ care (family history) and those discharged from nonstudy hospitals.